



Advances in Ebolavirus, Marburgvirus, and Cuevavirus Research

Collection Editor:

Dr. Jens H. Kuhn

NIH/NIAID Integrated Research
Facility at Fort Detrick (IRF-
Frederick), B-8200 Research
Plaza, Fort Detrick, Frederick, MD
21702, USA

kuhnjens@mail.nih.gov

Message from the Collection Editor

Dear Colleagues,

Filoviruses (cuevaviruses, ebolaviruses, and marburgviruses) are exotic high-consequence human and animal pathogens that must be handled in maximum (biosafety level 4) containment. This topic collection aims at providing an opportunity for filovirologists and other experts to publish not only general articles or reviews on any filovirus research topic, but also to distribute announcements of committee discussions or decisions, meeting reports, facility or method descriptions, and personal viewpoints or hypotheses. The goal of this open access topic collection is to further communication among interested scientists with particular emphasis on providing citable information on thoughts or ideas generally “known in the community” that are yet unpublished.

Sincerely,
Jens H. Kuhn





Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and
Replication Program, Center for
Cancer Research, National
Cancer Institute, Frederick, MD
21702-1201, USA

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section. Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the **Science Citation Index Expanded** (Web of Science), **MEDLINE** (PubMed) and other databases. Full-text available in PubMed Central.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 15.4 days after submission; acceptance to publication is undertaken in 4.1 days (median values for papers published in this journal in the second half of 2018).

Contact Us
